(redirected from Emtriva)
Also found in: Medical.
Related to Emtriva: Truvada, Viread


 (ĕm′trĭ-sĭt′ə-bēn′, -sī′tə-)
An antiviral drug, C8H10FN3O3S, that is a nucleoside reverse transcriptor inhibitor and is used in combination with other drugs to treat HIV infection or to reduce the risk of HIV infection.

[emtri- (probably Em(ory) University, where the drug was discovered + Tri(angle) Pharmaceuticals, company to which it was licensed) + -citabine, nucleoside analog antiviral and anticancer drug suff.; see zalcitabine.]


n emtricitabina
Mentioned in ?
References in periodicals archive ?
Contract award notice: Purchasing various medicines (18 lots) batch 11 - emtriva (emtricitabine) 200 mg (romania-arad: Various medicinal products)
In the years since 2012, when the Food and Drug Administration approved PrEP as an indication for 200 mg emtricitabine (Emtriva) and 300 mg tenofovir (Viread)--formulated into a single pill and marketed as Truvada--the idea of PrEP for people at increased risk for HIV exposure has gained traction.
(21.) Emtriva [package insert], Foster City, CA: Gilead Sciences, Inc.; 2017.
The company's HIV franchise includes Truvada, a combination of two of its other drugs, Viread and Emtriva.
Recombinant DNA, (2) stem cells, (3) genes, (4) and popular pharmaceuticals like Lyrica (5) and Emtriva (6) have driven university licensing revenue and, consequently, have been the primary focus of scholars studying invention on college campuses.
A newer drug in this class, called emtricitabine (Emtriva), treats both HIV and hepatitis B.
profiromycin, adriamycin Dementia Tacrine, galantamine Diabetes medication Metformin, troglitazone, rosiglitazone, buformin HIV/AIDS medications Atripla, combivir, emtriva, epivir.
In a phase IIIb randomized study, 89% of lamivudine-resistant patients with HBV who were randomly assigned to receive tenofovir (Viread) alone met the primary endpoint of HBV DNA below 400 copies/mL, compared with 86% of those assigned to a tenofovir/emtricitabine (Emtriva) combination, in an intention-to-treat analysis, reported Dr.
On August 2, 2012, Gilead Sciences, the world's largest maker of branded drugs to treat Human Immunodeficiency Virus (HIV), signed deals with Ranbaxy Laboratories, Strides Arcolab and Mylan to manufacture low-cost generic versions of its HIV drug Emtriva (emtricitabine) for sale in developing countries.
Gilead markets Emtricitabine under the brand name Emtriva, and a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate is available under the brand name Truvada.
Emtricitabine is marketed by Gilead under the brand name Emtriva, and a fixed-dose combination of Emtricitabine and Tenofovir Disoproxil Fumarate is made available under the brand name Truvada.
The antiretroviral combinations included many drugs in routine use today, such as Sustiva (efavirenz), Kaletra (lopinavir/ritonavir), Emtriva (emtricitabine), and Ziagen (abacavir).